R

emember January 2014? “Monster,” by Eminem and Rihanna was No. 1 in the U.S., while “Lone Survivor” topped the box office and, for a few days at least, Intercept Pharmaceuticals (ICPT) was a $450 stock.

It’s not anymore, as the chart below illustrates, and it fell about 25 percent further on Thursday after the FDA put out a note that the company’s lead drug, Ocaliva, increased the risk of liver injury and death in some patients. Intercept is down another 14 percent today.

Unlock this article by subscribing to STAT Plus today. Try it FREE for 30 days and cancel anytime!

SUBSCRIBE TODAY

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.

Privacy Policy